Barr Sees Rapid Uptake Of Allegra Generic, Downplays Impact From Competition
Barr/Teva's "at risk" generic of Sanofi-Aventis' fexofenadine antihistamine captures a 70% substitution rate with some large retailers in the first week after launch.
Barr/Teva's "at risk" generic of Sanofi-Aventis' fexofenadine antihistamine captures a 70% substitution rate with some large retailers in the first week after launch.